VivoSeq
Other

Gastrectomy

0

Pipeline Programs

5

Active Trials

1

Companies Involved

Gastrectomy is an early-stage landscape with 0 programs across 1 company. The most active players are Solvay Pharmaceuticals.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

21

clinical trials

Completed9 · 43%
Recruiting4 · 19%
Unknown status4 · 19%
Terminated2 · 10%
Withdrawn1 · 5%
Not yet recruiting1 · 5%

Trial Activity

21 trials

The Pancreatic Enzymes After Gastrectomy Trial
Recruiting·UUniversity of Leipzig·Phase 3·NCT06058442·188 enrolled
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Not yet recruiting··Phase 3·NCT06934655·150 enrolled
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
Completed·MMayo Clinic·Phase 3·NCT03115424·46 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)